The Significant Improvement of Survival Times and Pathological Parameters by Bioartificial Liver with Recombinant HepG2 in Porcine Liver Failure Model
We developed a bioartificial liver (BAL) containing human hepatoblastoma cell line, HepG2, with the addition of ammonia removal activity by transfecting a glutamine synthetase (GS) gene and estimated the efficacy using pigs with ischemic liver failure. GS-HepG2 cells showed 15% ammonia removal activ...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2006-11-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.3727/000000006783981350 |
id |
doaj-57487022985b41b6923b074d35cb6dfe |
---|---|
record_format |
Article |
spelling |
doaj-57487022985b41b6923b074d35cb6dfe2020-11-25T02:48:36ZengSAGE PublishingCell Transplantation0963-68971555-38922006-11-011510.3727/000000006783981350The Significant Improvement of Survival Times and Pathological Parameters by Bioartificial Liver with Recombinant HepG2 in Porcine Liver Failure ModelShin Enosawa0Tomoyuki Miyashita1Tomohiro Saito2Takeshi Omasa3Toshiharu Matsumura4 Department of Innovative Surgery, National Research Institute for Child Health and Development, Tokyo, Japan Department of Innovative Surgery, National Research Institute for Child Health and Development, Tokyo, Japan Epidemiology, National Research Institute for Child Health and Development, Tokyo, Japan Department of Biotechnology, Graduate School of Engineering, Osaka University, Osaka, Japan Roman Industries, Yokohama City, JapanWe developed a bioartificial liver (BAL) containing human hepatoblastoma cell line, HepG2, with the addition of ammonia removal activity by transfecting a glutamine synthetase (GS) gene and estimated the efficacy using pigs with ischemic liver failure. GS-HepG2 cells showed 15% ammonia removal activity of porcine hepatocytes, while unmodified HepG2 had no such activity. The established GS-HepG2 cells were grown in a circulatory flow bioreactor to 3.5–4.1 × 109 cells. Survival time of the animals treated with GS-HepG2 BAL was significantly prolonged compared to the cell-free control (14.52 ± 5.24 h vs. 8.53 ± 2.52 h) and the group treated with the BAL consisting of unmodified wild-type HepG2 (9.58 ± 4.52 h). Comparison showed the cell-containing BAL groups to have significantly fewer incidences of increased brain pressure. Thus, the GS-HepG2 BAL treatment resulted in a significant improvement of survival time and pathological parameters in pigs with ischemic liver failure.https://doi.org/10.3727/000000006783981350 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shin Enosawa Tomoyuki Miyashita Tomohiro Saito Takeshi Omasa Toshiharu Matsumura |
spellingShingle |
Shin Enosawa Tomoyuki Miyashita Tomohiro Saito Takeshi Omasa Toshiharu Matsumura The Significant Improvement of Survival Times and Pathological Parameters by Bioartificial Liver with Recombinant HepG2 in Porcine Liver Failure Model Cell Transplantation |
author_facet |
Shin Enosawa Tomoyuki Miyashita Tomohiro Saito Takeshi Omasa Toshiharu Matsumura |
author_sort |
Shin Enosawa |
title |
The Significant Improvement of Survival Times and Pathological Parameters by Bioartificial Liver with Recombinant HepG2 in Porcine Liver Failure Model |
title_short |
The Significant Improvement of Survival Times and Pathological Parameters by Bioartificial Liver with Recombinant HepG2 in Porcine Liver Failure Model |
title_full |
The Significant Improvement of Survival Times and Pathological Parameters by Bioartificial Liver with Recombinant HepG2 in Porcine Liver Failure Model |
title_fullStr |
The Significant Improvement of Survival Times and Pathological Parameters by Bioartificial Liver with Recombinant HepG2 in Porcine Liver Failure Model |
title_full_unstemmed |
The Significant Improvement of Survival Times and Pathological Parameters by Bioartificial Liver with Recombinant HepG2 in Porcine Liver Failure Model |
title_sort |
significant improvement of survival times and pathological parameters by bioartificial liver with recombinant hepg2 in porcine liver failure model |
publisher |
SAGE Publishing |
series |
Cell Transplantation |
issn |
0963-6897 1555-3892 |
publishDate |
2006-11-01 |
description |
We developed a bioartificial liver (BAL) containing human hepatoblastoma cell line, HepG2, with the addition of ammonia removal activity by transfecting a glutamine synthetase (GS) gene and estimated the efficacy using pigs with ischemic liver failure. GS-HepG2 cells showed 15% ammonia removal activity of porcine hepatocytes, while unmodified HepG2 had no such activity. The established GS-HepG2 cells were grown in a circulatory flow bioreactor to 3.5–4.1 × 109 cells. Survival time of the animals treated with GS-HepG2 BAL was significantly prolonged compared to the cell-free control (14.52 ± 5.24 h vs. 8.53 ± 2.52 h) and the group treated with the BAL consisting of unmodified wild-type HepG2 (9.58 ± 4.52 h). Comparison showed the cell-containing BAL groups to have significantly fewer incidences of increased brain pressure. Thus, the GS-HepG2 BAL treatment resulted in a significant improvement of survival time and pathological parameters in pigs with ischemic liver failure. |
url |
https://doi.org/10.3727/000000006783981350 |
work_keys_str_mv |
AT shinenosawa thesignificantimprovementofsurvivaltimesandpathologicalparametersbybioartificialliverwithrecombinanthepg2inporcineliverfailuremodel AT tomoyukimiyashita thesignificantimprovementofsurvivaltimesandpathologicalparametersbybioartificialliverwithrecombinanthepg2inporcineliverfailuremodel AT tomohirosaito thesignificantimprovementofsurvivaltimesandpathologicalparametersbybioartificialliverwithrecombinanthepg2inporcineliverfailuremodel AT takeshiomasa thesignificantimprovementofsurvivaltimesandpathologicalparametersbybioartificialliverwithrecombinanthepg2inporcineliverfailuremodel AT toshiharumatsumura thesignificantimprovementofsurvivaltimesandpathologicalparametersbybioartificialliverwithrecombinanthepg2inporcineliverfailuremodel AT shinenosawa significantimprovementofsurvivaltimesandpathologicalparametersbybioartificialliverwithrecombinanthepg2inporcineliverfailuremodel AT tomoyukimiyashita significantimprovementofsurvivaltimesandpathologicalparametersbybioartificialliverwithrecombinanthepg2inporcineliverfailuremodel AT tomohirosaito significantimprovementofsurvivaltimesandpathologicalparametersbybioartificialliverwithrecombinanthepg2inporcineliverfailuremodel AT takeshiomasa significantimprovementofsurvivaltimesandpathologicalparametersbybioartificialliverwithrecombinanthepg2inporcineliverfailuremodel AT toshiharumatsumura significantimprovementofsurvivaltimesandpathologicalparametersbybioartificialliverwithrecombinanthepg2inporcineliverfailuremodel |
_version_ |
1724747636549877760 |